Bluejay Therapeutics, Inc. announced that it will issue 27,711,910 series C preferred shares at a price of $6.5266 per share for gross proceeds of $180,864,551.806, and 173,980 series C-1 preferred share at a price of $6.5266 per share for gross proceeds of $1,135,497.868, for aggregate gross proceeds of $182,000,049.674 on April 30, 2024. The shares have a par value of $0.00001 per share. The shares carry non-cumulative fixed dividend rate of 8% per share.

The shares will be convertible into common shares at a fixed conversion price of $6.5266 per share. The company will receive $181,999,946 pursuant to exemption provided under Regulation D.